Manulife (Manufacturers Life Insurance)
CRNX

Manulife (Manufacturers Life Insurance)’s Crinetics Pharmaceuticals CRNX Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.71M Sell
125,948
-21,732
-15% -$808K ﹤0.01% 1214
2026
Q1 		$5.36M Sell
147,680
-809
-0.5% -$36.1K ﹤0.01% 1135
2025
Q4 		$7M Buy
148,489
+676
+0.5% +$30.1K 0.01% 1050
2025
Q3 		$6.16M Sell
147,813
-7,167
-5% -$229K 0.01% 1092
2025
Q2 		$4.46M Buy
154,980
+20,187
+15% +$623K ﹤0.01% 1216
2025
Q1 		$4.52M Sell
134,793
-14,163
-10% -$529K ﹤0.01% 1207
2024
Q4 		$7.62M Buy
148,956
+14,869
+11% +$832K 0.01% 1017
2024
Q3 		$6.85M Buy
134,087
+3,024
+2% +$156K 0.01% 1078
2024
Q2 		$5.87M Buy
131,063
+23,398
+22% +$1.08M 0.01% 1100
2024
Q1 		$5.04M Buy
107,665
+26,699
+33% +$1.04M ﹤0.01% 1190
2023
Q4 		$2.88M Buy
80,966
+17,083
+27% +$524K ﹤0.01% 1355
2023
Q3 		$1.9M Buy
63,883
+12,723
+25% +$262K ﹤0.01% 1453
2023
Q2 		$922K Buy
51,160
+30,745
+151% +$613K ﹤0.01% 1699
2023
Q1 		$328K Hold
20,415
– – ﹤0.01% 2251
2022
Q4 		$374K Buy
20,415
+22
+0.1% +$388 ﹤0.01% 2167
2022
Q3 		$401K Sell
20,393
-447
-2% -$9.12K ﹤0.01% 2123
2022
Q2 		$389K Buy
20,840
+2,880
+16% +$57.5K ﹤0.01% 2213
2022
Q1 		$394K Sell
17,960
-4,090
-19% -$82.8K ﹤0.01% 2337
2021
Q4 		$626K Buy
22,050
+1,849
+9% +$45.6K ﹤0.01% 2119
2021
Q3 		$425K Sell
20,201
-1,599
-7% -$33.4K ﹤0.01% 2414
2021
Q2 		$411K Buy
21,800
+4,481
+26% +$78.7K ﹤0.01% 2571
2021
Q1 		$265K Buy
17,319
+76
+0.4% +$1.18K ﹤0.01% 2696
2020
Q4 		$243K Buy
17,243
+830
+5% +$11.6K ﹤0.01% 2649
2020
Q3 		$257K Hold
16,413
– – ﹤0.01% 2402
2020
Q2 		$293K Buy
+16,413
New +$280K ﹤0.01% 2270

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s CRNX Position: Q2 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its Crinetics Pharmaceuticals (CRNX) stake by 15% in Q2 2026, selling an estimated $808K and leaving 125,948 shares worth $4.71M. The position accounts for ﹤0.01% of the portfolio, ranked #1214.

Manulife (Manufacturers Life Insurance) first reported a position in CRNX in Q2 2020 and has held it in 25 quarters since. The position peaked at $7.62M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Manulife (Manufacturers Life Insurance) held 125,948 shares of Crinetics Pharmaceuticals worth $4.71M as of Q2 2026.
  • Manulife (Manufacturers Life Insurance) sold 21,732 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $808K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q2 2026, its #1214 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Crinetics Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Crinetics Pharmaceuticals position peaked at $7.62M in Q4 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2026, filed 14 Aug 2026.